Tetrahydronaphthalene derivative and application thereof to preparing medicine for preventing and/or treating breast cancer osteoporosis

Abstract

The invention relates to a novel tetrahydronaphthalene derivative and application thereof to preparing a medicine for preventing and / or treating breast cancer osteoporosis. The tetrahydronaphthalene derivative disclosed by the invention is an ideal selective estrogen receptor modulator and can be used for treating or preventing various indications relative to estrogen, in particular breast cancer osteoporosis after menopause. The tetrahydronaphthalene derivative has lower oxidative metabolism and higher effective bioavailability, therefore having the advantages of less application dosage, better tolerance and little side effect.

Description

technical field [0001] The invention relates to a tetralin derivative and its use in the preparation of drugs for preventing and / or treating breast cancer and osteoporosis. Background technique [0002] Selective estrogen receptor modulators (selective estrogen receptor modulators, SERMs) refer to a series of compounds with different structures that can interact with estrogen receptors and produce specific effects according to different target tissues and hormone internal environments. It exhibits estrogen-like effects in some tissues and anti-estrogen-like effects in other tissues. A selective estrogen receptor modulator that has estrogen-like effects on bone and cardiovascular system, anti-estrogen-like effects on breast and uterus, and no side effects such as endometrial cancer and vascular complications is desired. [0003] At present, the selective estrogen receptor modulators in clinical trials or clinical use mainly include triphenylethylene derivatives (Triphenyleth...

AI Technical Summary

Problems solved by technology

In addition, the water solubility of raloxifene is very low, only 2ug / ml

Images